The anti-tumorigenic properties of ApoA1 have been recently studied (Su et al., 2010; Ganapathy et al., 2012; Gao et al., 2012; Zamanian-Daryoush et al., 2013; Gkouskou et al., 2016) and it was found that ApoA1 and ApoA1 mimetic peptides can bind to pro-inflammatory pro-oncogenic phospholipids, namely to lysophosphatidic acid (LPA) (Van Lenten et al., 2008; Su et al., 2010; Yeh et al., 2016), whose plasma levels are increased in approximately 90% of all ovarian cancer patients (Bast et al., 2009). The gene discussed is APOA1; the disease is ovarian cancer.